Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) has issued a 18-month, $4.8m contract to Nanotherapeutics for development of oral radiation drug.
Subscribe to our email newsletter
Nanotherapeutics will conduct studies to develop an improved formulation of diethylenetriaminepentaacetate (DTPA) and improve manufacturing its processes.
DTPA can bind radioactive molecules to help the body remove them thereby treating people who have taken in radioactive particles.
The improved formulation, NanoDTPA is being developed as a short-term treatment for people exposed to radioactive elements like americium, curium, or plutonium.
DTPA should be administered intravenously or by nebulizer, as per the US Food and Drug Administration